Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa.
Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa.
复制标题
DOI：
10.1371/journal.pone.0174117
复制
发表时间：
2017
期刊：
影响因子：
3.7
通讯作者：
HARP Study Group
中科院分区：
文献类型：
--
作者：
Kelly HA;Ngou J;Chikandiwa A;Sawadogo B;Gilham C;Omar T;Lompo O;Doutre S;Meda N;Weiss HA;Delany-Moretlwe S;Segondy M;Mayaud P;HARP Study Group
描述布基纳法索 (BF) 和南非 (SA) 感染艾滋病毒 (WLHIV) 的女性中高危人乳头瘤病毒 (HR-HPV) 与高级别宫颈上皮内瘤变 (CIN2+) 的关联。前往艾滋病毒门诊和治疗中心就诊的 WLHIV 人群。招聘按 ART 状态分层。使用 INNO-LiPA 进行宫颈 HPV 基因分型，并对入组时和 16 个月后的 4 象限宫颈活检进行组织学评估。在基线时患有 CIN2+ 的女性中，二价/四价 (HPV16/18) 或非价 (HPV16/18/31/35/45/52/58) HPV 疫苗中包含的任何 HR-HPV 基因型的患病率范围为 37% 至 90%。 HPV58 与 CIN2+ 的相关性最强（aOR = 5.40，95% CI：2.77–10.53）。在 16 个月的随访中，任何 HR-HPV 的持续存在与 CIN2+ 事件密切相关（aOR = 7.90，95% CI：3.11–20.07），HPV16/18 的持续存在（aOR = 5.25，95% CI：2.14–12.91）和非价疫苗中的其他 HR 类型（aOR = 3.23， 95%CI：1.23–8.54）。 HR-HPV 持续存在在非洲 WLHIV 中非常常见，并且与 CIN2+ 事件相关。 HPV 疫苗可以预防非洲 WLHIV 中 37-90% 的 CIN2+。
To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA). Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres. Recruitment was stratified by ART status. Cervical HPV genotyping using INNO-LiPA and histological assessment of 4-quadrant cervical biopsies at enrolment and 16 months later. Among women with CIN2+ at baseline, the prevalence of any HR-HPV genotypes included in the bi/quadrivalent (HPV16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines ranged from 37% to 90%. HPV58 was most strongly associated with CIN2+ (aOR = 5.40, 95%CI: 2.77–10.53). At 16-months follow-up, persistence of any HR-HPV was strongly associated with incident CIN2+ (aOR = 7.90, 95%CI: 3.11–20.07), as was persistence of HPV16/18 (aOR = 5.25, 95%CI: 2.14–12.91) and the additional HR types in the nonavalent vaccine (aOR = 3.23, 95%CI: 1.23–8.54). HR-HPV persistence is very common among African WLHIV and is linked to incident CIN2+. HPV vaccines could prevent between 37–90% of CIN2+ among African WLHIV.